In order to thoroughly standardize the order of drug market operation and ensure the safety and effectiveness of drug use by the masses, since the beginning of this year, all localities have been focusing on key areas, paying close attention to key links, and ensuring drug safety.
On October 27, the Guangdong Provincial Food and Drug Administration issued a notice
on the results of drug business supervision, inspection and assessment.
The content of the notice pointed out that the provincial drug regulatory bureau recently organized the supervision and inspection of 199 pharmaceutical trading enterprises, and the inspection results were all basically in line with the requirements; The provincial bureau requires these 199 pharmaceutical companies to strictly implement the main responsibility, rectify the defective projects, and report the implementation of
rectification to the local market supervision and management department in a timely manner.
Prior to this, the Guangdong Provincial Drug Administration also issued a notice on drug spot check and inspection information (Issue 5 of 2022).
From the "List of Sampled Drugs (Issue 5 of 2022)", it can be found that the drugs of many pharmaceutical companies have been exposed
due to unqualified detection content determination and weight difference items.
Among them, it includes 1 batch of Banlan root granules produced by Hengtuo Group Nanning Rensheng Pharmaceutical Co.
, Ltd.
, 1 batch of multi-dimensional element tablets produced by Shanghai Huayuan Anhui Jinhui Pharmaceutical Co.
, Ltd.
(21), and 1 batch of compound aminophenol alkanamine tablets produced by Shanghai Beijie Group Kanto Pharmaceutical Co.
, Ltd
.
In addition to Guangdong, the Anhui Provincial Food and Drug Administration also issued a notice on drug production supervision and inspection information on
the 27th.
According to the content of the notice, the provincial bureau has carried out routine inspections, rectification and re-inspections, and cause inspections for
45 pharmaceutical companies.
Among them, 36 companies meet the requirements, and 8 basically meet the requirements and need rectification
.
At present, most of them have been rectified; One enterprise that does not meet the requirements is Anhui City Pharmaceutical Co.
, Ltd.
, and the provincial bureau has ordered it to suspend production, warn and rectify
.
On October 26, the Liaoning Food and Drug Administration issued a public notice on the inspection of production enterprises, and three enterprises, Xifeng Min Helu Product Processing Co.
, Ltd.
, Tieling Lubaotang Pharmaceutical Group Co.
, Ltd.
, and Tieling Duji Plaster Factory, underwent GMP daily supervision and inspection, and found a total of 9 types of defects
.
On October 25, the Jiangsu Food and Drug Administration issued a notice on the results of random inspection of drug quality, and there were also 4 batches of random inspection of drugs that did not meet the regulations, all of which were traditional Chinese medicine pieces, of which 3 batches of manufacturers replied that they had not produced the sampling products, involving drinking pieces: epimedium, wheat dong, peony peel, and sand garden; For drugs that do not meet the regulations, the drug regulatory department has required relevant enterprises to take risk control measures
such as suspension of sales and use, recall, etc.
.
.
.
.
.
.
According to incomplete statistics, since October, there have been hundreds of illegal punishments
due to various inspections by provincial drug administrations across the country.
Frequent random inspections mean that the state pays more and more attention to the pharmaceutical industry, especially in recent years, the supervision of the pharmaceutical industry by relevant institutions is still becoming stricter
.
Industry analysts believe that although there are still some chaos in the pharmaceutical market, among which drug quality problems also occur from time to time, with the increase of national and local supervision and inspection frequency, it has slowly changed the atmosphere of the pharmaceutical industry and will accelerate its development
towards a benign trend.
At the same time, for pharmaceutical companies, they need to pay more attention to strictly following laws and regulations and controlling the production quality of all links, so as to better improve the ability and level of controlling the challenges of drug safety risks; At the same time, we must continue to improve the competitiveness
of the product market through continuous innovation and upgrading.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice
to anyone.
={"common":{"bdSnsKey":{},"bdText":"","bdMini":"1","bdMiniList":false,"bdPic":"","bdStyle":"0","bdSize":"32"},"share":{},"image":{"viewList":[" weixin","sqq","qzone","tsina","tqq","tsohu","tieba","renren","youdao","fx","ty","fbook","twi","copy","print"],"viewText":"Share to:","viewSize":"24"},"selectShare":{" bdContainerClass":null,"bdSelectMiniList":["weixin","sqq","qzone","tsina","tqq","tsohu","tieba","renren","youdao","fx","ty","fbook","twi","copy","print"]}}; with(document)0[(getElementsByTagName('head')[0]|| body).
appendChild(createElement('script')).
src='http://bdimg.
share.
baidu.
com/static/api/js/share.
js?v=89860593.
js?cdnversion='+~(-new Date()/36e5)]; 
